The activation of genes associated with the IL-5, IL-6, and IL-17 signaling pathways, as well as with T-cell immune response in patients with well-controlled T2D when compared with poorly controlled T2D, may indicate a better regulation of the immune response in patients with well-controlled T2D [23]. The gene discussed is IL17A; the disease is type 2 diabetes mellitus.